Global Therapeutic Vaccines Market Statistics: USD 75.1 Billion Value by 2033
Summary:
- The global therapeutic vaccines industry size reached USD 34.3 Billion in 2024.
- The market is expected to reach USD 75.1 Billion by 2033, exhibiting a growth rate (CAGR) of 9.03% during 2025-2033.
- North America leads the market, accounting for the largest therapeutic vaccines market share.
- Tumor cell vaccines account for the majority of the market share in the type segment, which can be attributed to their ability to target cancer cells and offer a highly focused approach to treatment.
- Autoimmune disease vaccines hold the largest share in the therapeutic vaccines industry.
- Autologous vaccines remain a dominant segment in the market due to the rising focus on reducing toxicity concerns associated with traditional treatments like chemotherapy.
- On the basis of distribution channel, the market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies.
- The rising prevalence of chronic diseases is a primary driver of the therapeutic vaccines market.
- The increasing investment in research and development (R&D) activities and advancements in vaccine technology are reshaping the therapeutic vaccines market.
Industry Trends and Drivers:
- Growing Prevalence of Chronic Diseases:
Such diseases like cancer, autoimmune diseases and infectious diseases are on the increase thereby promoting the need for therapeutic vaccines. It is worth underlining that many chronic diseases thus entail the need of their long-term follow-up, or the application of new interventional approaches to their detection. Therapeutic vaccines are ideal to complement other therapeutic approaches in that they strengthen the immune system responses against certain disease cells or pathogens. Select cancer therapeutic vaccines stimulate the patient’s immune system to target tumor cells, which may enhance the client’s prognosis. Since the population age is gradually growing older worldwide, many chronic illnesses are on the rise, and thus require new treatment modalities. There is increasing interest in creating vaccines that would afford sustained/latented protective immunity or regulation of these diseases.
- Rising Investment in Research and Development:
The market mainly receives a boost from increased R&D expenditure by governments and other stakeholders, and global private entities. Higher funding means better and more complicated clinical trials, probing new treatments and method of treatment, as well as novel types of vaccines. More managing bodies, non-profit organizations, and private companies in many countries are realizing that therapeutic vaccines with potential to fill the gaps in the industry present good opportunities that they can fund or partner. Currently, funding programmes that have been earmarked to fund the advancement of vaccines including the Coalition for Epidemic Preparedness Innovations (CEPI) and several government grants finance the development of therapeutic or what may be described as preventive vaccines, especially in the fields of infectious diseases and into cancer.
- Advancements In Vaccine Technology:
New advance in vaccines has gone along way in enhancing therapeutic vaccines through increased efficacy, safety and methods of delivery. We can identify progressive developments of vaccine technologies, for instance, mRNA technology, viral vector platforms. For instance, mRNA platforms can be easily developed and tweaked for tailored vaccines for new diseases as the world is experiencing right now with covid-19. At the same time, the given technologies help develop vaccines that trigger prolonged and potent immune responses to offer higher efficacy in chronic and infective states. This gives some idea of the interest in the therapeutic vaccines; ongoing work on nanoparticle vaccines and other new delivery approaches also raise the likelihood of therapeutic vaccines. Since the growth of such technologies, they have received a lot of attention from both pharmaceutical firms and investors.
Request for a sample copy of this report:Â https://www.imarcgroup.com/therapeutic-vaccines-market/requestsample
Therapeutic Vaccines Market Report Segmentation:
Breakup By Type:
- Antigen Vaccines
- Dendritic Cell Vaccine
- DNA Vaccine
- Tumor Cell Vaccines
Tumor cell vaccines account for the majority of shares, which can be attributed to their ability to target cancer cells and offer a highly focused approach to treatment.
Breakup By Disease Type:
- Autoimmune Disease Vaccines
- Addiction Vaccine
- Neurological Disease Vaccine
- Infectious Disease Vaccine
- Others
Autoimmune disease vaccines dominate the market as they offer a potential alternative by stimulating immune tolerance and reducing the need for immunosuppression.
Breakup By Technology:
- Autologous Vaccines
- Allogeneic Vaccine
Autologous vaccines represent the majority of shares due to the rising focus on reducing toxicity concerns associated with traditional treatments like chemotherapy.
Breakup By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
On the basis of distribution channel, the market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies.
Breakup By Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America enjoys the leading position owing to a large market for therapeutic vaccines driven by the presence of well-developed healthcare infrastructure.
Top Therapeutic Vaccines Market Leaders:
The therapeutic vaccines market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:
- Agenus Inc.
- Argos Therapeutics Inc.
- Bavarian Nordic A/S
- Cel-Sci Corporation
- CSL Limited
- Emergent Biosolutions Inc.
- GSK plc
- Merck & Co. Inc.
- Pfizer Inc.
- Sanofi S.A.
Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email:Â sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
